tiprankstipranks
Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé
Company Announcements

Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé

Don't Miss our Black Friday Offers:

An update from Seres Therapeutics ( (MCRB) ) is now available.

Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Science, enhancing its financial standing and honing its focus on developing live biotherapeutics for patients at high risk of severe bacterial infections. The deal includes an immediate cash payment and potential future milestone payments, based on VOWST’s net sales, totaling up to $275 million. Additionally, Seres will provide transition services to facilitate the business handover, while retaining a non-exclusive license to certain intellectual property. The agreement also involves SPN’s purchase of Seres’ common stock and an employee support arrangement to ensure a smooth transition.

See more data about MCRB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskSeres Therapeutics Reports Q3 2024 Results and Strategic Progress
TheFlySeres reports Q3 EPS from continuing operations (33c), consensus (24c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App